Literature DB >> 30344205

Molecular mechanisms and clinical features of heart failure.

Satoshi Suzuki1,2, Yasuchika Takeishi1.   

Abstract

Heart failure (HF) is a common disease with high prevalence, mortality in hospitalization and after discharge, readmission rates, and burden on healthcare system. Activation of the inflammatory systems is an important role for HF progression, and pentraxin 3 (PTX3) is one of the inflammatory markers. The plasma PTX3 levels increased with advancing the HF severity, and high levels of plasma PTX3 indicated poor prognosis in HF patients. Moreover, we demonstrated that PTX3 had the crucial role for cardiac remodeling under pressure overload using two different genotypes of mice: PTX3 systemic knockout mice and transgenic mice with cardiac-specific overexpression of PTX3.Diuretics are the essential drug for HF treatment, and we designed multicenter, randomized study for evaluating the efficacy and safety of tolvaptan compared to carperitide. Daily urine volume and serum sodium levels were significantly higher, and cardiovascular events were significantly lower in the tolvaptan group than in the carperitide group. Moreover, we investigated the influence of great earthquake in HF patients, and found out that moving into temporary housing by earthquake might affect the incidence of re-hospitalization due to worsening HF.In this review article, we would introduce our research on HF which has various aspects as described above.

Entities:  

Keywords:  diuretics; earthquake; heart failure; inflammation; prognosis

Mesh:

Substances:

Year:  2018        PMID: 30344205      PMCID: PMC6305784          DOI: 10.5387/fms.2018-17

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  23 in total

Review 1.  Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility.

Authors:  Cecilia Garlanda; Barbara Bottazzi; Antonio Bastone; Alberto Mantovani
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

2.  Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry.

Authors:  W Franklin Peacock; Maria Rosa Costanzo; Teresa De Marco; Margarita Lopatin; Janet Wynne; Roger M Mills; Charles L Emerman
Journal:  Cardiology       Date:  2008-10-17       Impact factor: 1.869

3.  Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction.

Authors:  R J Raymond; G J Dehmer; T C Theoharides; E N Deliargyris
Journal:  Am Heart J       Date:  2001-03       Impact factor: 4.749

Review 4.  The role of interleukin-6 in the failing heart.

Authors:  K C Wollert; H Drexler
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

5.  Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

Authors:  Lisa C Costello-Boerrigter; William B Smith; Guido Boerrigter; John Ouyang; Christopher A Zimmer; Cesare Orlandi; John C Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2005-09-27

6.  Relation of loop diuretic dose to mortality in advanced heart failure.

Authors:  Shervin Eshaghian; Tamara B Horwich; Gregg C Fonarow
Journal:  Am J Cardiol       Date:  2006-04-27       Impact factor: 2.778

7.  Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study.

Authors:  Noritake Hata; Yoshihiko Seino; Takayoshi Tsutamoto; Shinya Hiramitsu; Noboru Kaneko; Tsutomu Yoshikawa; Hiroyuki Yokoyama; Keiji Tanaka; Kyoichi Mizuno; Jun Nejima; Masahiko Kinoshita
Journal:  Circ J       Date:  2008-09-24       Impact factor: 2.993

8.  Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure.

Authors:  Wei-Hsian Yin; Jaw-Wen Chen; Hsu-Lung Jen; Meng-Cheng Chiang; Wen-Pin Huang; An-Ning Feng; Mason Shing Young; Shing-Jong Lin
Journal:  Am Heart J       Date:  2004-05       Impact factor: 4.749

9.  Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study.

Authors:  Fumihiro Nomura; Nobushige Kurobe; Yoshihiro Mori; Atsushi Hikita; Masanori Kawai; Mitsuru Suwa; Yukihiro Okutani
Journal:  Circ J       Date:  2008-10-03       Impact factor: 2.993

10.  Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.

Authors:  Satoshi Suzuki; Yasuchika Takeishi; Takeshi Niizeki; Yo Koyama; Tatsuro Kitahara; Toshiki Sasaki; Mina Sagara; Isao Kubota
Journal:  Am Heart J       Date:  2007-09-27       Impact factor: 4.749

View more
  1 in total

1.  Light Emitting Diodes Photobiomodulation Improves Cardiac Function by Promoting ATP Synthesis in Mice With Heart Failure.

Authors:  Wenwen Zhang; Xinlu Gao; Xiuxiu Wang; Desheng Li; Yiming Zhao; Tingting Zhang; Jingwen Ne; Binbin Xu; Shuainan Li; Zuke Jiang; Hongyue Sun; Wenya Ma; Fan Yang; Benzhi Cai; Baofeng Yang
Journal:  Front Cardiovasc Med       Date:  2021-12-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.